Methods and Compositions for Treatment of Restenosis
Description of Invention:
This application describes the use of antisense oligonucleotides designed to inhibit osteopontin production, and their use in treating restenosis, the reocclusion of an artery following angioplasty. Utilizing blood samples and coronary artery tissues from patients it was demonstrated that OPN levels are increased both in the atherosclerotic tissues as well as in the blood following angioplasty. Further, using an in vitro system employing human coronary artery smooth muscle cell culture (CASMC), it has been demonstrated that these antisense molecules inhibit osteopontin expression.
This research has been published in PNAS USA 94(19):9308-13 (August 18, 1997).
Inventors:
AB Mukherjee (NICHD) GC Kundu (NICHD) DK Panda (NICHD)
Patent Status:
DHHS Reference No. E-163-1996/0 --
U.S. Patent 6,458,590 issued 01 Oct 2002
Portfolios: Internal Medicine
Internal Medicine-Therapeutics
For Additional Information Please Contact: Surekha Vathyam Ph.D.
Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301/435-4076
Email: vathyams@mail.nih.gov
Fax: 301/402-0220
